Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Immunotherapy for TB.

Doherty TM.

Immunotherapy. 2012 Jun;4(6):629-47. doi: 10.2217/imt.12.52. Review.

PMID:
22788130
2.

A novel DNA vaccine containing multiple TB-specific epitopes cast in a natural structure elicits enhanced Th1 immunity compared with BCG.

Gao H, Li K, Yu S, Xiong S.

Microbiol Immunol. 2009 Oct;53(10):541-9. doi: 10.1111/j.1348-0421.2009.00157.x.

3.

Immunogenicity and therapeutic effects of Ag85A/B chimeric DNA vaccine in mice infected with Mycobacterium tuberculosis.

Liang Y, Wu X, Zhang J, Xiao L, Yang Y, Bai X, Yu Q, Li Z, Bi L, Li N, Wu X.

FEMS Immunol Med Microbiol. 2012 Dec;66(3):419-26. doi: 10.1111/1574-695X.12008.

4.

Prime-boost BCG vaccination with DNA vaccines based in β-defensin-2 and mycobacterial antigens ESAT6 or Ag85B improve protection in a tuberculosis experimental model.

Cervantes-Villagrana AR, Hernández-Pando R, Biragyn A, Castañeda-Delgado J, Bodogai M, Martínez-Fierro M, Sada E, Trujillo V, Enciso-Moreno A, Rivas-Santiago B.

Vaccine. 2013 Jan 11;31(4):676-84. doi: 10.1016/j.vaccine.2012.11.042. Epub 2012 Nov 26.

PMID:
23196205
5.

Immunogenicity and protective efficacy against murine tuberculosis of a prime-boost regimen with BCG and a DNA vaccine expressing ESAT-6 and Ag85A fusion protein.

Lu J, Wang C, Zhou Z, Zhang Y, Cao T, Shi C, Chen Z, Chen L, Cai C, Fan X.

Clin Dev Immunol. 2011;2011:617892. doi: 10.1155/2011/617892. Epub 2011 Feb 27.

6.

Protection against Mycobacterium tuberculosis challenge in mice by DNA vaccine Ag85A-ESAT-6-IL-21 priming and BCG boosting.

Dou J, Wang Y, Yu F, Yang H, Wang J, He X, Xu W, Chen J, Hu K.

Int J Immunogenet. 2012 Apr;39(2):183-90. doi: 10.1111/j.1744-313X.2011.01066.x. Epub 2011 Dec 8.

PMID:
22152009
7.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
8.

The Ag85B protein of Mycobacterium tuberculosis may turn a protective immune response induced by Ag85B-DNA vaccine into a potent but non-protective Th1 immune response in mice.

Palma C, Iona E, Giannoni F, Pardini M, Brunori L, Orefici G, Fattorini L, Cassone A.

Cell Microbiol. 2007 Jun;9(6):1455-65. Epub 2007 Jan 22.

PMID:
17250590
9.

[Recent progress in mycobacteriology].

Okada M, Kobayashi K.

Kekkaku. 2007 Oct;82(10):783-99. Japanese.

PMID:
18018602
10.

Differential protective efficacy of DNA vaccines expressing secreted proteins of Mycobacterium tuberculosis.

Kamath AT, Feng CG, Macdonald M, Briscoe H, Britton WJ.

Infect Immun. 1999 Apr;67(4):1702-7.

11.

Mapping of murine Th1 helper T-Cell epitopes of mycolyl transferases Ag85A, Ag85B, and Ag85C from Mycobacterium tuberculosis.

D'Souza S, Rosseels V, Romano M, Tanghe A, Denis O, Jurion F, Castiglione N, Vanonckelen A, Palfliet K, Huygen K.

Infect Immun. 2003 Jan;71(1):483-93.

12.

A recombinant adenovirus expressing immunodominant TB antigens can significantly enhance BCG-induced human immunity.

Hoft DF, Blazevic A, Stanley J, Landry B, Sizemore D, Kpamegan E, Gearhart J, Scott A, Kik S, Pau MG, Goudsmit J, McClain JB, Sadoff J.

Vaccine. 2012 Mar 9;30(12):2098-108. doi: 10.1016/j.vaccine.2012.01.048. Epub 2012 Jan 30.

PMID:
22296955
13.

Recognition of stage-specific mycobacterial antigens differentiates between acute and latent infections with Mycobacterium tuberculosis.

Demissie A, Leyten EM, Abebe M, Wassie L, Aseffa A, Abate G, Fletcher H, Owiafe P, Hill PC, Brookes R, Rook G, Zumla A, Arend SM, Klein M, Ottenhoff TH, Andersen P, Doherty TM; VACSEL Study Group.

Clin Vaccine Immunol. 2006 Feb;13(2):179-86.

14.

Interaction of Mycobacterium tuberculosis with the host: consequences for vaccine development.

Dietrich J, Doherty TM.

APMIS. 2009 May;117(5-6):440-57. doi: 10.1111/j.1600-0463.2009.02458.x. Review.

PMID:
19400867
15.

Immunity to TB and targets for immunotherapy.

Gonzalez-Juarrero M.

Immunotherapy. 2012 Feb;4(2):187-99. doi: 10.2217/imt.11.168. Review.

PMID:
22339461
16.

Immunotherapy for tuberculosis: what's the better choice?

Guo S, Zhao J.

Front Biosci (Landmark Ed). 2012 Jun 1;17:2684-90. Review.

PMID:
22652806
17.

Pulmonary necrosis resulting from DNA vaccination against tuberculosis.

Taylor JL, Turner OC, Basaraba RJ, Belisle JT, Huygen K, Orme IM.

Infect Immun. 2003 Apr;71(4):2192-8.

18.

Exposure to Mycobacterium avium decreases the protective effect of the DNA vaccine pVAXhsp65 against Mycobacterium tuberculosis-induced inflammation of the pulmonary parenchyma.

Martins DR, Pelizon AC, Zorzella-Pezavento SF, Seger J, Santos Junior RR, Fonseca DM, Justulin LA Jr, Silva CL, Sartori A.

Scand J Immunol. 2011 Apr;73(4):293-300. doi: 10.1111/j.1365-3083.2011.02510.x.

19.

Human T cell and antibody-mediated responses to the Mycobacterium tuberculosis recombinant 85A, 85B, and ESAT-6 antigens.

Macedo GC, Bozzi A, Weinreich HR, Bafica A, Teixeira HC, Oliveira SC.

Clin Dev Immunol. 2011;2011:351573. doi: 10.1155/2011/351573. Epub 2010 Dec 29.

20.

Lack of immune responses to Mycobacterium tuberculosis DosR regulon proteins following Mycobacterium bovis BCG vaccination.

Lin MY, Geluk A, Smith SG, Stewart AL, Friggen AH, Franken KL, Verduyn MJ, van Meijgaarden KE, Voskuil MI, Dockrell HM, Huygen K, Ottenhoff TH, Klein MR.

Infect Immun. 2007 Jul;75(7):3523-30. Epub 2007 May 14.

Items per page

Supplemental Content

Write to the Help Desk